Literature DB >> 1827081

Exclusive expression of MHC class II proteins on CD45+ cells in pancreatic islets of NOD mice.

M F McInerney1, S Rath, C A Janeway.   

Abstract

The expression of MHC class II molecules on beta-cells of the pancreatic islet has been proposed to play a role in the genesis of insulin-dependent diabetes mellitus in the NOD mouse. We investigated this by immunofluorescent double labeling of islet cells with anti-MHC and anti-CD45 to identify cells of hematopoietic origin. MHC class I expression increased with age on CD45- islet cells. MHC class II expression was not observed on CD45- islet cells at any age; the only cells in the islet that were MHC class II positive were also CD45+. This indicates that all MHC class II-positive cells in the islet are lymphoid cells that infiltrate the islet, whereas the islet endocrine cells express no MHC class II molecules. However, an increase in MHC class I expression occurred on beta-cells, and this may play a role in immunopathogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827081     DOI: 10.2337/diab.40.5.648

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

1.  Low incidence of autoimmune type I diabetes in BB rats fed a hydrolysed casein-based diet associated with early inhibition of non-macrophage-dependent hyperexpression of MHC class I molecules on beta cells.

Authors:  X B Li; F W Scott; Y H Park; J W Yoon
Journal:  Diabetologia       Date:  1995-10       Impact factor: 10.122

2.  Adenovirus early region 3 transgenes expressed in beta cells prevent autoimmune diabetes in nonobese diabetic mice: effects of deleting the adenovirus death protein 11.6K.

Authors:  Melissa A Pierce; Anton Svetlanov; Marshall S Horwitz; David V Serreze
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes.

Authors:  A Amrani; J Verdaguer; S Thiessen; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

Authors:  Eli C Lewis; Leland Shapiro; Owen J Bowers; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

5.  Prevalent CD8(+) T cell response against one peptide/MHC complex in autoimmune diabetes.

Authors:  B Anderson; B J Park; J Verdaguer; A Amrani; P Santamaria
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

6.  Natural killer cell depletion and diabetes mellitus in the BB/Wor rat (revisited).

Authors:  K Ellerman; M Wrobleski; A Rabinovitch; A Like
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

7.  Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice.

Authors:  L Wen; F S Wong; L Burkly; M Altieri; C Mamalaki; D Kioussis; R A Flavell; R S Sherwin
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

8.  Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes.

Authors:  U Walter; T Toepfer; K E J Dittmar; K Kretschmer; J Lauber; S Weiss; G Servos; O Lechner; W A Scherbaum; S R Bornstein; H Von Boehmer; J Buer
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

9.  Insulitis in transgenic mice expressing tumor necrosis factor beta (lymphotoxin) in the pancreas.

Authors:  D E Picarella; A Kratz; C B Li; N H Ruddle; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Beta cell MHC class I is a late requirement for diabetes.

Authors:  Emma E Hamilton-Williams; Stephanie E Palmer; Brett Charlton; Robyn M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.